Skip to main content
HHS
NASDAQ Trade & Services

Harte Hanks Reports Q1 2026 Results: Revenue Down 10.3%, Net Loss Worsens 60.2% Amid Operational Challenges

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
7
Price
$2.81
Mkt Cap
$20.836M
52W Low
$2.22
52W High
$5.39
Market data snapshot near publication time

summarizeSummary

Harte Hanks reported a 10.3% revenue decrease and a 60.2% higher net loss in Q1 2026, with operating losses widening significantly, though operating cash burn improved and substantial credit remains available.


check_boxKey Events

  • Q1 2026 Revenue Decline

    Revenue decreased by 10.3% to $37.3 million in Q1 2026, down from $41.6 million in Q1 2025, with all segments experiencing declines.

  • Worsening Net Loss

    Net loss increased by 60.2% to $0.6 million in Q1 2026, compared to a net loss of $0.4 million in the prior year quarter.

  • Significant Operating Loss Increase

    Operating loss widened substantially to $0.8 million in Q1 2026 from $0.04 million in Q1 2025, indicating a deterioration in core operational performance.

  • Improved Operating Cash Flow

    Net cash used in operating activities improved to $0.6 million in Q1 2026, compared to $0.8 million used in Q1 2025.


auto_awesomeAnalysis

Harte Hanks' Q1 2026 results show a significant 10.3% revenue decline and a 60.2% increase in net loss compared to the prior year, indicating worsening profitability. The operating loss widened substantially from $0.04 million to $0.77 million, reflecting core operational challenges. While cash and equivalents decreased, the company improved its net cash used in operating activities, and maintains a substantial $24.3 million in available credit, providing a buffer against current losses. This detailed quarterly report follows a high-level announcement, providing critical insights into the company's financial health and segment performance.

At the time of this filing, HHS was trading at $2.81 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $20.8M. The 52-week trading range was $2.22 to $5.39. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed HHS - Latest Insights

HHS
May 15, 2026, 8:16 AM EDT
Filing Type: 10-Q
Importance Score:
7
HHS
May 14, 2026, 4:24 PM EDT
Filing Type: 8-K
Importance Score:
7
HHS
Mar 17, 2026, 5:20 PM EDT
Filing Type: 10-K
Importance Score:
7